Literature DB >> 30930338

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.

Anita Kumar1, Zhitao Ying2,3, Anna Alperovich2,4, Ahmet Dogan2, Paul Hamlin2, Craig Moskowitz2,5, Janine Pichardo2, Carol Portlock2, Fushen Sha2, Andrew D Zelenetz2, Zhigang Zhang2, Esther Drill2, Kaitlin Woo2,6, Anas Younes2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30930338      PMCID： PMC6442955          DOI： 10.3324/haematol.2018.201350

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

Authors:  Anna Abrahamsson; Alexandra Albertsson-Lindblad; Peter N Brown; Stefanie Baumgartner-Wennerholm; Lars M Pedersen; Francesco D'Amore; Herman Nilsson-Ehle; Paw Jensen; Michael Pedersen; Christian H Geisler; Mats Jerkeman
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.

Authors:  C Royo; A Navarro; G Clot; I Salaverria; E Giné; P Jares; D Colomer; A Wiestner; W H Wilson; M C Vegliante; V Fernandez; E M Hartmann; N Trim; W N Erber; S H Swerdlow; W Klapper; M J S Dyer; M Vargas-Pabón; G Ott; A Rosenwald; R Siebert; A López-Guillermo; E Campo; S Beà
Journal:  Leukemia       Date:  2012-03-19       Impact factor: 11.528

3.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

4.  TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.

Authors:  Christian W Eskelund; Christina Dahl; Jakob W Hansen; Maj Westman; Arne Kolstad; Lone B Pedersen; Carmen P Montano-Almendras; Simon Husby; Catja Freiburghaus; Sara Ek; Anja Pedersen; Carsten Niemann; Riikka Räty; Peter Brown; Christian H Geisler; Mette K Andersen; Per Guldberg; Mats Jerkeman; Kirsten Grønbæk
Journal:  Blood       Date:  2017-08-17       Impact factor: 22.113

5.  Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index.

Authors:  Yoshizo Kimura; Kensaku Sato; Yutaka Imamura; Fumiko Arakawa; Junichi Kiyasu; Masanori Takeuchi; Hiroaki Miyoshi; Maki Yoshida; Daisuke Niino; Yasuo Sugita; Toshiaki Morito; Tadashi Yoshino; Shigeo Nakamura; Koichi Ohshima
Journal:  Cancer Sci       Date:  2011-06-23       Impact factor: 6.716

6.  Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.

Authors:  Jonathon B Cohen; Xuesong Han; Ahmedin Jemal; Elizabeth M Ward; Christopher R Flowers
Journal:  Cancer       Date:  2016-05-06       Impact factor: 6.860

7.  Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis.

Authors:  Sarah L Ondrejka; Raymond Lai; Stephen D Smith; Eric D Hsi
Journal:  Haematologica       Date:  2011-04-20       Impact factor: 9.941

8.  Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

Authors:  P Solal-Céligny; E Lepage; N Brousse; C L Tendler; P Brice; C Haïoun; J Gabarre; B Pignon; G Tertian; R Bouabdallah; J F Rossi; C Doyen; B Coiffier
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

9.  Observation as the initial management strategy in patients with mantle cell lymphoma.

Authors:  P Abrisqueta; D W Scott; G W Slack; C Steidl; A Mottok; R D Gascoyne; J M Connors; L H Sehn; K J Savage; A S Gerrie; D Villa
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

10.  A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Authors:  Guillem Clot; Pedro Jares; Eva Giné; Alba Navarro; Cristina Royo; Magda Pinyol; David Martín-Garcia; Santiago Demajo; Blanca Espinet; Antonio Salar; Ana Ferrer; Ana Muntañola; Marta Aymerich; Hilka Rauert-Wunderlich; Elaine S Jaffe; Joseph M Connors; Randy D Gascoyne; Jan Delabie; Armando López-Guillermo; German Ott; George W Wright; Louis M Staudt; Andreas Rosenwald; David W Scott; Lisa M Rimsza; Sílvia Beà; Elías Campo
Journal:  Blood       Date:  2018-05-16       Impact factor: 25.476
View more
  6 in total

Review 1.  Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Authors:  Danielle Wallace; Patrick M Reagan
Journal:  Drugs       Date:  2021-03-30       Impact factor: 9.546

Review 2.  CAR T-Cell Therapy in the Older Person: Indications and Risks.

Authors:  Geoffrey Shouse; Alexey V Danilov; Andy Artz
Journal:  Curr Oncol Rep       Date:  2022-04-14       Impact factor: 5.945

Review 3.  How we treat mature B-cell neoplasms (indolent B-cell lymphomas).

Authors:  Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe
Journal:  J Hematol Oncol       Date:  2021-01-06       Impact factor: 17.388

4.  Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Authors:  Eva Giné; Fátima de la Cruz; Ana Jiménez Ubieto; Javier López Jimenez; Alejandro Martín García-Sancho; M José Terol; Eva González Barca; María Casanova; Adolfo de la Fuente; Ana Marín-Niebla; Ana Muntañola; Tomás José González-López; Marta Aymerich; Xavier Setoain; Montserrat Cortés-Romera; Amanda Rotger; Sonia Rodríguez; Alejandro Medina Herrera; Ramón García Sanz; Ferran Nadeu; Silvia Beà; Elías Campo; Armando López-Guillermo
Journal:  J Clin Oncol       Date:  2022-01-14       Impact factor: 44.544

5.  Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.

Authors:  Alessia Castellino; Yucai Wang; Melissa C Larson; Matthew J Maurer; Brian K Link; Umar Farooq; Andrew L Feldman; Sergei I Syrbu; Thomas M Habermann; Jonas Paludo; David J Inwards; Thomas E Witzig; Stephen M Ansell; Cristine Allmer; Susan L Slager; Jonathon B Cohen; Peter Martin; James R Cerhan; Grzegorz S Nowakowski
Journal:  Blood Adv       Date:  2022-02-22

Review 6.  Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.

Authors:  Pavel Klener
Journal:  Int J Mol Sci       Date:  2019-09-08       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.